BR112019004877A2 - novos compostos e usos terapêuticos dos mesmos - Google Patents

novos compostos e usos terapêuticos dos mesmos

Info

Publication number
BR112019004877A2
BR112019004877A2 BR112019004877A BR112019004877A BR112019004877A2 BR 112019004877 A2 BR112019004877 A2 BR 112019004877A2 BR 112019004877 A BR112019004877 A BR 112019004877A BR 112019004877 A BR112019004877 A BR 112019004877A BR 112019004877 A2 BR112019004877 A2 BR 112019004877A2
Authority
BR
Brazil
Prior art keywords
new compounds
therapeutic uses
compounds
pathogen
bind
Prior art date
Application number
BR112019004877A
Other languages
English (en)
Inventor
Watson Christine
Glossop Melanie
Westby Michael
Original Assignee
Centauri Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1615560.8A external-priority patent/GB201615560D0/en
Priority claimed from GBGB1707076.4A external-priority patent/GB201707076D0/en
Application filed by Centauri Therapeutics Ltd filed Critical Centauri Therapeutics Ltd
Publication of BR112019004877A2 publication Critical patent/BR112019004877A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • C07K7/62—Polymyxins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

a invenção refere-se a novos compostos com a capacidade de ligar uma resposta imune a um patógeno, ao uso dos ditos compostos em uma doença ou transtorno mediado e/ou causado por um agente infeccioso, às composições contendo os ditos compostos, processos para sua preparação e a novos intermediários usados no dito processo.
BR112019004877A 2016-09-13 2017-09-13 novos compostos e usos terapêuticos dos mesmos BR112019004877A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1615560.8A GB201615560D0 (en) 2016-09-13 2016-09-13 Novel compounds and therapeutic uses thereof
GBGB1707076.4A GB201707076D0 (en) 2017-05-04 2017-05-04 Novel compounds and therapeutic uses thereof
PCT/GB2017/052699 WO2018051085A1 (en) 2016-09-13 2017-09-13 Novel compounds and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
BR112019004877A2 true BR112019004877A2 (pt) 2019-06-11

Family

ID=59923474

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019004877A BR112019004877A2 (pt) 2016-09-13 2017-09-13 novos compostos e usos terapêuticos dos mesmos

Country Status (14)

Country Link
US (1) US11014966B2 (pt)
EP (1) EP3512544B1 (pt)
JP (2) JP7185622B2 (pt)
KR (1) KR102544465B1 (pt)
CN (1) CN110022896B (pt)
AU (1) AU2017328896A1 (pt)
BR (1) BR112019004877A2 (pt)
CA (1) CA3036405A1 (pt)
DK (1) DK3512544T3 (pt)
ES (1) ES2854991T3 (pt)
IL (1) IL265269B (pt)
MX (1) MX2019002879A (pt)
WO (1) WO2018051085A1 (pt)
ZA (1) ZA201901422B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201705686D0 (en) * 2017-04-07 2017-05-24 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
GB201804098D0 (en) * 2018-03-14 2018-04-25 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
GB201904534D0 (en) 2019-04-01 2019-05-15 Centauri Therapeutics Ltd Novel compounds an therapeutic uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7645743B2 (en) * 1999-12-22 2010-01-12 Altermune, Llc Chemically programmable immunity
CN1747970A (zh) * 2003-02-06 2006-03-15 三肽公司 抗原/抗体或配体/受体糖基化的特异性交换剂
AU2004268497A1 (en) * 2003-02-28 2005-03-10 Antigenics Inc. Use of lectins to promote oligomerization of glycoproteins and antigenic molecules
EP2430033A4 (en) * 2009-05-05 2012-11-07 Altermune Technologies Llc CHEMICALLY PROGRAMMABLE IMMUNITY
EP2780357A1 (en) * 2011-11-18 2014-09-24 Novacta Biosystems Limited Polymyxin derivatives
WO2016104647A1 (ja) * 2014-12-25 2016-06-30 国立大学法人大阪大学 糖鎖結合ワクチン抗原及び糖鎖導入剤
GB201517859D0 (en) * 2015-10-08 2015-11-25 Altermune Ltd Novel compounds and therapeutic uses thereof

Also Published As

Publication number Publication date
WO2018051085A1 (en) 2018-03-22
KR102544465B1 (ko) 2023-06-19
CN110022896B (zh) 2023-12-19
CN110022896A (zh) 2019-07-16
ES2854991T3 (es) 2021-09-23
EP3512544A1 (en) 2019-07-24
JP7185622B2 (ja) 2022-12-07
IL265269A (en) 2019-05-30
JP2022184922A (ja) 2022-12-13
KR20190064592A (ko) 2019-06-10
DK3512544T3 (da) 2021-02-01
US20190248838A1 (en) 2019-08-15
US11014966B2 (en) 2021-05-25
AU2017328896A1 (en) 2019-04-04
ZA201901422B (en) 2020-11-25
JP2019526614A (ja) 2019-09-19
EP3512544B1 (en) 2020-10-28
IL265269B (en) 2022-04-01
CA3036405A1 (en) 2018-03-22
MX2019002879A (es) 2019-09-18

Similar Documents

Publication Publication Date Title
BR112016024644A2 (pt) vacinas de ácido nucleico
CY1124756T1 (el) Εξουδετερωτικα αντισωματα του ιου ανθρωπινης ανοσοανεπαρκειας
CL2017002767A1 (es) Nuevas proteínas específicas para cd137.
BR112018000632A2 (pt) moléculas de anticorpo que ligam a cd79
BR112017016417A2 (pt) moléculas de ligação dirigidas contra hemaglutinina da gripe e seus usos
BR112017017949A2 (pt) regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna
BR112017012327A8 (pt) benzamidas substituídas por 1,3-tiazol-2-il.
BR112018000604A2 (pt) moléculas de anticorpo que ligam cd45
BR112016029906A2 (pt) compostos excipientes redutores de viscosidade para formulações proteicas
EA201991207A1 (ru) Новые агонисты tnfr и их применение
BR112015026830A8 (pt) composto, composição farmacêutica, combinação, produto, uso de um composto, e, método para profilaxia ou tratamento de um estado de doença ou condição
DOP2017000191A (es) Nuevas proteínas específicas para pioverdina y pioquelina
BR112017009545A2 (pt) composição antibacteriana, método para a preparação de uma composição, bacteriófago, ácido nucleico isolado, polipeptídeo isolado, e uso de um bacteriófago, ácido nucleico ou polipeptídeo
BR112018073676A2 (pt) lipossomas peguilados e métodos de uso
BR112017003346A2 (pt) derivados de pirazolopiridina, seus usos, e composição farmacêutica
BR112016020377A2 (pt) proteínas fc multiméricas
BR112017008416A2 (pt) ?produtos terapêuticos à base de lantionina sintetase c-like 2?.
BR112015030229A8 (pt) Partícula semelhante a vírus compreendendo um polipeptídeo e um antígeno da malária, vetor, composições farmacêutica e de vacina, bem como molécula de ácido nucleico isolado
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
BR112019004877A2 (pt) novos compostos e usos terapêuticos dos mesmos
CY1119957T1 (el) Θεραπεια νοσηματων με τη χρηση ανοχογονου φαρμακευτικου παρασκευασματος
BR112017011556A2 (pt) métodos para gerar um anticorpo sintético, prevenir ou tratar uma doença, tratar um sujeito de infecção por um patógeno e um sujeito com câncer, produto, molécula de ácido nucleico, e, composição.
BR112016028037A2 (pt) Novos compostos
BR112017014376A2 (pt) formulação aquosa estável de anticorpos antifator de crescimento endotelial vascular (vegf) e uso
BR112017002173A2 (pt) anticorpos semelhantes à angiopoietina e métodos de uso

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]